Sakudo, Akikazu, Kuratsune, Hirohiko, Kobayashi, Takanori et al. · Biochemical and biophysical research communications · 2006 · DOI
Researchers used a special light-based scanning technique to analyze blood samples from ME/CFS patients and healthy people. The scans could correctly identify which samples came from ME/CFS patients about 93% of the time. This suggests that a simple blood test using this technology might one day help doctors diagnose ME/CFS objectively, rather than relying only on symptoms and other tests.
ME/CFS currently lacks objective diagnostic biomarkers, forcing clinicians to rely on clinical criteria and exclusion of other conditions. A non-invasive blood-based spectroscopic test could improve diagnostic accuracy, reduce diagnostic delay, and potentially identify biochemical abnormalities underlying the disease. This work contributes to the growing body of evidence that ME/CFS has detectable biological signatures in blood.
This study does not prove that the observed spectral differences reflect the cause of ME/CFS or explain which biochemical components drive the discrimination. It does not establish whether spectral changes are disease-specific or could occur in other conditions. The study cannot be generalized beyond the specific populations tested without larger, independent validation cohorts.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.